Cardiovascular Endocrinology

REWIND Trial: Dulaglutide and cardiovascular outcomes in type 2 diabetes

The REWIND trial aimed to assess the cardiovascular (CV) safety of dulaglutide, a glucagon-like peptide-1 (GLP-1) agonist, in patients with type 2 diabetes mellitus at higher risk for CV events. The trial involved 9,901 patients and randomized them to dulaglutide and compared outcomes with placebo. The results of the REWIND trial indicated that once-weekly dulaglutide administered via subcutaneous injection is superior to placebo in improving glycemic control and reducing CV events in patients with type 2 diabetes and higher CV risk. There was also a significant reduction in nonfatal strokes and improvement in the composite renal outcomes. Source: Lancet